Heart Failure

A systematic review and network meta-analysis is comparing 9 classes of therapies for HbA1c and risk management in patients with low versus increased cardiovascular risk.

New research suggests the microbiome from the tongue coating of patients with heart failure contains unique differences to those of healthy patients.

A new study found newly diagnosed type 2 diabetics who develop heart failure had the highest risk of death versus patients with other CVDs or chronic kidney disease.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.

A new study from the University of Arizona is shedding light on the psychological impact of Tai Chi in patients with cardiovascular disease.

Despite normally being associated with end of life care, new research suggest palliative care could benefit heart failure patients.

A new systematic review and meta-analysis is shedding light on the potential impact of inadequate health literacy on mortality and hospitalizations in heart failure patients.

New research suggests combining agents from the 3 classes could pay major dividends in terms of event-free and overall survival.

Individuals with obstructive sleep apnea were more frequently male, obese, and had more coronary heart disease when compared to those without OSA.

A new research letter has found declines in rural areas have not been as pronounced as declines in metropolitan areas.

New research suggests a group of 6 cancer biomarkers was associated with all-cause mortality and HF hospitalizations.

After receiving approval for a similar indication in type 2 diabetics in late 2019, the FDA has approved dapagliflozin for reducing risk of CV death and hospitalization in patients with HFrEF.

The latest scientific statement from the AHA addresses cardiovascular considerations before, during, and after pregnancy.